Alnylam Pharmaceuticals, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
8
Bullish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
ALNY
Consensus analyst target of $449.48 is 52% above current price.
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $449.48 (+51.8%)
25 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
ALNY
JNJ
74.6×
Trailing P/E
26.3×
21.2×
Forward P/E
17.9×
12.6%
Profit Margin
21.8%
80.8%
Gross Margin
68.0%
90.4%
ROE
26.4%
96.4%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
0.38
Beta
0.33
—
Price / Book
—
$39.5B
Market Cap
$546.9B
$246 – $496
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →